The Committee noted that the demonstration of Kivexa’ s benefit was mainly based on one study in adults, most of whom had not received previous treatment for HIV infection and had no symptoms of HIV infection.
Komitee märkis, et Kivexa kasulikkust tõendati põhiliselt ühe uuringuga, mis korraldati täiskasvanutega, kellest enamikul ei oldud HIV- nakkust varem ravitud ja kellel puudusid HIV- nakkuse sümptomid.